Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Condition:   Diffuse Large B-Cell Lymphoma Interventions:   Drug: Orelabrutinib;   Biological: Rituximab;   Drug: CHOP-like Regimen Sponsor:   The First Affiliated Hospital of Soochow University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 12, 2022 Category: Research Source Type: clinical trials

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition:   Diffuse Large B-cell Lymphoma Interventions:   Drug: Polatuzumab vedotin (PV);   Drug: Rituximab;   Drug: Hyaluronidase;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Dexamethasone;   Drug: GCSF Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 11, 2022 Category: Research Source Type: clinical trials

A Study of ELAPRASE in Treatment-na ïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
Conditions:   Mucopolysaccharidosis (MPS);   Hunter Syndrome Interventions:   Drug: ELAPRASE;   Drug: Rituximab;   Drug: Methotrexate;   Drug: Intravenous Immunoglobulin (IVIG) Sponsors:   Takeda;   Takeda Development Center Americas, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 10, 2022 Category: Research Source Type: clinical trials

A Pilot " Window-3 " Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Conditions:   Lymphoma;   Mantle Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Drug: Rituximab;   Other: Brexucabtagene Autoleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate Sponsors:   M.D. Anderson Cancer Center;   Kite, A Gilead Company;   Acerta Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 10, 2022 Category: Research Source Type: clinical trials

A Study of ELAPRASE in Treatment-na ïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
Conditions:   Mucopolysaccharidosis (MPS);   Hunter Syndrome Interventions:   Drug: ELAPRASE;   Drug: Rituximab;   Drug: Methotrexate;   Drug: Intravenous Immunoglobulin (IVIG) Sponsors:   Takeda;   Takeda Development Center Americas, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 10, 2022 Category: Research Source Type: clinical trials

A Pilot " Window-3 " Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Conditions:   Lymphoma;   Mantle Cell Lymphoma Interventions:   Drug: Acalabrutinib;   Drug: Rituximab;   Other: Brexucabtagene Autoleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate Sponsors:   M.D. Anderson Cancer Center;   Kite, A Gilead Company;   Acerta Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 10, 2022 Category: Research Source Type: clinical trials

A Study of ELAPRASE in Treatment-na ïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
Conditions:   Mucopolysaccharidosis (MPS);   Hunter Syndrome Interventions:   Drug: ELAPRASE;   Drug: Rituximab;   Drug: Methotrexate;   Drug: Intravenous Immunoglobulin (IVIG) Sponsors:   Takeda;   Takeda Development Center Americas, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 10, 2022 Category: Research Source Type: clinical trials